Patients are significantly more likely to experience treatment-related cardiac events with osimertinib than with other EGFR TKIs, data suggest.
A two-drug combination extended OS compared with standard first-line osimertinib for certain patients with advanced lung ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback